腹腔镜肝切除治疗非结直肠肝转移的围术期与长期结局
本回顾性研究分析2000至2018年间接受腹腔镜肝切除的结直肠肝转移与非结直肠肝转移患者,比较围术期及长期结局。非结直肠非神经内分泌肝转移患者复发无生存与总生存较差,但手术安全可行,在多学科管理下积极手术可能使部分患者长期生存获益。
要点
- 腹腔镜肝切除治疗非结直肠肝转移安全可行,围术期死亡率低。
- 非结直肠非神经内分泌肝转移的3年与5年无复发生存率分别为33%与20.8%。
- 在多学科管理下,积极手术(包括复杂及重复肝切除)可能改善部分患者长期生存。
核心结论
- 腹腔镜肝切除在多学科管理背景下对经过选择的非结直肠非神经内分泌肝转移患者安全可行,积极手术可能带来长期生存获益。
研究设计与样本
- 回顾性研究,从2000至2018年前瞻性维护的数据库中选择接受腹腔镜肝切除的结直肠肝转移与非结直肠肝转移患者,比较临床病理、手术及短期和长期结局。
主要发现
- 主要术后并发症率在结直肠肝转移组为12.7%,神经内分泌肝转移组为19%,非结直肠非神经内分泌肝转移组为3.6%(p=0.001)。
- 死亡率在结直肠肝转移组为0.6%,非结直肠肝转移组为0。
- R1手术切缘率在各组间相当(p=0.432)。
- 3年和5年无复发生存率:结直肠肝转移组分别为76.1%和64.3%,神经内分泌肝转移组分别为57.1%和42.3%,非结直肠非神经内分泌肝转移组分别为33%和20.8%(p=0.001)。
- 3年和5年总生存率:结直肠肝转移组分别为88.3%和82.7%,神经内分泌肝转移组分别为85.7%和70.6%,非结直肠非神经内分泌肝转移组分别为71.4%和52.9%(p=0.001)。
临床怎么用
- 对于经过选择的非结直肠非神经内分泌肝转移患者,在多学科管理框架下可考虑积极的手术策略,包括复杂肝切除和复发后的重复肝切除。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Liver is a common metastatic site not only of colorectal but of non-colorectal neoplasms, as well. However, resection of non-colorectal liver metastases (NCRLMs) remains controversial. The aim of this retrospective study was to analyze the short- and long-term outcomes of patients undergoing laparoscopic liver resection (LLR) for NCRLMs. METHODS: From a prospectively maintained database between 2000 and 2018, patients undergoing LLR for colorectal liver metastases (CRLMs) and NCRLMs were selected. Clinicopathologic, operative, short- and long-term outcome data were collected, analyzed, and compared among patients with CRLMs and NCRLMs. RESULTS: The primary tumor was colorectal in 354 (82.1%), neuroendocrine in 21 (4.9%), and non-colorectal, non-neuroendocrine in the remaining 56 (13%) patients. Major postoperative morbidities were 12.7%, 19%, and 3.6%, respectively (p = 0.001), whereas the mortality was 0.6% for patients with CRLMs and zero for patients with NCRLMs. The rate of R1 surgical margin was comparable (p = 0.432) among groups. According to the survival analysis, 3- and 5-year recurrence-free survival (RFS) rates were 76.1% and 64.3% in the CRLM group, 57.1% and 42.3% in the neuroendocrine liver metastase (NELM) group, 33% and 20.8% in the non-colorectal, non-neuroendocrine liver metastase (NCRNNELM) group (p = 0.001), respectively. Three- and 5-year overall survival (OS) rates were 88.3% and 82.7% in the CRLM group, 85.7% and 70.6% in the NELM group, 71.4% and 52.9% in the NCRNNELM group (p = 0.001), respectively. In total, 113 out of 354 (31.9%) patients with CRLMs, 2 out of 21(9.5%) with NELMs, and 8 out of 56 (14.3%) patients with NCRNNELMs underwent repeat LLR for recurrent metastatic tumors. CONCLUSION: LLR is safe and feasible in the context of a multimodal management where an aggressive surgical approach, necessitating even complex procedures for bilobar multifocal metastases and repeat hepatectomy for recurrences, is the mainstay and may be of benefit in the long-term survival, in selected patients with NCRNNELMs.
引用
- Triantafyllidis I, Gayet B, Tsiakyroudi S, et al. Perioperative and long-term outcomes of laparoscopic liver resections for non-colorectal liver metastases. Surg Endosc. 2019. PMID: 31586246. doi:10.1007/s00464-019-07148-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。